{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:10:06Z","timestamp":1788174606576,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.blre.2023.101163","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T19:01:20Z","timestamp":1702234880000},"page":"101163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Richter's transformation: Transforming the clinical landscape"],"prefix":"10.1016","volume":"64","author":[{"given":"A.","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Appleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.A.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.blre.2023.101163_bb0005","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101163_bb0010","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL study group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.blre.2023.101163_bb0020","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","article-title":"Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: a Nationwide epidemiological study","volume":"61","author":"Ben-Dali","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.blre.2023.101163_bb0025","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter\u2019s transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101163_bb0035","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish chronic lymphocytic Leukemia study group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101163_bb0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.blre.2023.101163_bb0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.blre.2023.101163_bb0050","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.18241","article-title":"Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia","volume":"198","author":"Zhu","year":"2022","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101163_bb0055","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"issue":"15","key":"10.1016\/j.blre.2023.101163_bb0060","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101163_bb0065","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2019.240564","article-title":"The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica."},{"issue":"10","key":"10.1016\/j.blre.2023.101163_bb0070","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter\u2019s syndrome: a report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101163_bb0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000269737","article-title":"Cutaneous Richter\u2019s syndrome, prognosis, and clinical, histological and immunohistological patterns: report of four cases and review of the literature","volume":"220","author":"Duong","year":"2010","journal-title":"Dermatology."},{"issue":"6","key":"10.1016\/j.blre.2023.101163_bb0080","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1211::AID-CNCR21>3.0.CO;2-1","article-title":"Hypercalcemia may indicate Richter\u2019s syndrome: report of four cases and review","volume":"79","author":"Beaudreuil","year":"1997","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<99::AID-AJH3>3.0.CO;2-T","article-title":"Epstein-Barr virus infection in Richter\u2019s transformation","volume":"60","author":"Ansell","year":"1999","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/path.5060","article-title":"Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia","volume":"245","author":"Garc\u00eda-Barchino","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.blre.2023.101163_bb0095","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","article-title":"Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion","volume":"55","author":"Xiao","year":"2016","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.blre.2023.101163_bb0100","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00277-018-3390-x","article-title":"Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales","volume":"97","author":"Federmann","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101163_bb0105","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/his.13024","article-title":"Diagnostic dilemmas of high-grade transformation (Richter\u2019s syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review","volume":"69","author":"Soilleux","year":"2016","journal-title":"Histopathology."},{"issue":"9","key":"10.1016\/j.blre.2023.101163_bb0110","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gin\u00e9","year":"2010","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0115","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/bjh.16948","article-title":"Pseudo-Richter transformation of chronic lymphocytic leukaemia\/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall","volume":"191","author":"Barnea Slonim","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/jh517","article-title":"Herpes simplex necrotic lymphadenitis masquerading as Richter\u2019s transformation in treatment-naive patients with chronic lymphocytic Leukemia","volume":"8","author":"Hodgson","year":"2019","journal-title":"J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101163_bb0125","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.clml.2020.12.003","article-title":"2-[(18)F]-FDG PET\/CT role in detecting Richter transformation of chronic lymphocytic Leukemia and predicting overall survival","volume":"21","author":"Albano","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.blre.2023.101163_bb0130","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18F-FDG-PET maximum standardized uptake value>10 represents a novel valid marker for discerning Richter\u2019s syndrome","volume":"57","author":"Michallet","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.blre.2023.101163_bb0135","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3324\/haematol.2018.207068","article-title":"Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy","volume":"104","author":"Mato","year":"2019","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0140","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/10428194.2013.802313","article-title":"2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","volume":"55","author":"Papaj\u00edk","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic value of baseline Total metabolic tumor volume measured on FDG PET in patients with Richter syndrome","volume":"45","author":"Pontoizeau","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0150","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.blre.2023.101163_bb0155","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.blre.2023.101163_bb0160","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2023.101163_bb0165","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.blre.2023.101163_bb0170","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"issue":"15","key":"10.1016\/j.blre.2023.101163_bb0175","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood."},{"issue":"20","key":"10.1016\/j.blre.2023.101163_bb0180","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0185","first-page":"11","article-title":"Richter syndrome: novel insights into the biology of transformation","volume":"142","author":"Parry","year":"2023","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101163_bb0190","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1002\/ajh.23826","article-title":"Richter\u2019s transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL study group","volume":"89","author":"Tadmor","year":"2014","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101163_bb0195","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1002\/ajh.26239","article-title":"Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French innovative Leukemia organization","volume":"96","author":"Moulin","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.blre.2023.101163_bb0205","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to Ibrutinib in chronic lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2023.101163_bb0210","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line Venetoclax combinations in chronic lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101163_bb0215","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","article-title":"Richter\u2019s syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101163_bb0220","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3324\/haematol.2020.256388","article-title":"Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration","volume":"106","author":"Stephens","year":"2021","journal-title":"Haematologica."},{"issue":"12","key":"10.1016\/j.blre.2023.101163_bb0225","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0230","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic Leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.26755","article-title":"Patient characteristics that predict Richter\u2019s transformation in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"98","author":"Kittai","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2023.101163_bb0240","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41409-023-01978-6","article-title":"Allogeneic hematopoietic cell transplantation for Richter transformation of chronic lymphocytic leukemia: an intention-to-transplant analysis","volume":"58","author":"Puckrin","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2023.101163_bb0245","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter\u2019s syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"18","key":"10.1016\/j.blre.2023.101163_bb0260","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.blre.2023.101163_bb0265","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.blre.2023.101163_bb0270","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/bloodadvances.2020003726","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter\u2019s transformation","volume":"5","author":"Lahoud","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2023.101163_bb0275","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/bjh.17882","article-title":"Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology good practice paper","volume":"196","author":"Eyre","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0280","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.hemonc.2020.05.002","article-title":"Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: a systematic review and meta-analysis","volume":"14","author":"Aulakh","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"14","key":"10.1016\/j.blre.2023.101163_bb0285","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1200\/JCO.2014.58.6750","article-title":"Outcomes of patients with chronic lymphocytic Leukemia and Richter\u2019s transformation after transplantation failure","volume":"33","author":"Rozovski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101163_bb0290","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2022-158807","article-title":"Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: a Lysa study from the Descar-T registry","volume":"140","author":"Bensaber","year":"2022","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2023.101163_bb0295","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101163_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.828471","article-title":"Results of ARI-0001 CART19 cells in patients with chronic lymphocytic Leukemia and Richter\u2019s transformation","volume":"12","author":"Ortiz-Maldonado","year":"2022","journal-title":"Front Oncol"},{"issue":"26","key":"10.1016\/j.blre.2023.101163_bb0305","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic Leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101163_bb0310","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2022-157058","article-title":"Efficacy of Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1\/2 BRUIN study","volume":"140","author":"Wierda","year":"2022","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101163_bb0315","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101163_bb0320","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000870","article-title":"Zanubrutinib, alone and in combination with Tislelizumab, for the treatment of Richter transformation of chronic lymphocytic Leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Hemasphere."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101163_bb0325","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101163_bb0330","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0335","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101163_bb0340","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1182\/blood-2022-159695","article-title":"Blinatumomab for patients with Richter syndrome: final results of the phase 2 Blinart trial from the filo group","volume":"140","author":"Guieze","year":"2022","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2023.101163_bb0345","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101163_bb0350","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous Epcoritamab in patients with Richter\u2019s syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101163_bb0355","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1182\/blood-2022-163509","article-title":"Waveline-001: updated results from a phase 1 dose escalation and cohort expansion study of Zilovertamab Vedotin (MK-2140) in non-Hodgkin lymphoma","volume":"140","author":"Spurgeon","year":"2022","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101163_bb0360","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101163_bb0365","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1182\/blood-2021-153947","article-title":"Ibrutinib combined with Obinutuzumab and CHOP (I-OCHOP) for Richter transformation","volume":"138","author":"Lopez","year":"2021","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101163_bb0370","doi-asserted-by":"crossref","first-page":"9871","DOI":"10.1182\/blood-2022-169986","article-title":"Updated results from a phase I\/II study of Duvelisib and Venetoclax in patients with relapsed or refractory (R\/R) chronic lymphocytic Leukemia (CLL) or Richter\u2019s syndrome (RS)","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0375","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101163_bb0380","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101163_bb0385","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1182\/blood-2021-149320","article-title":"A phase I trial of PI3K\u03b1\u03b4 inhibitor Copanlisib in combination with Nivolumab in patients with Richter\u2019s transformation (RT) or transformed non-Hodgkin lymphoma (tNHL)","volume":"138","author":"Shouse","year":"2021","journal-title":"Blood."},{"issue":"Suppl","key":"10.1016\/j.blre.2023.101163_bb0390","article-title":"S147: efficacy and safety results of molto, a multicenter, open label, phase ii clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in richter syndrome","volume":"7","author":"Frustaci","year":"2023","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101163_bb0395","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2021-154279","article-title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 checkpoint inhibitor) for treatment for patients with Richter transformation","volume":"138","author":"Jain","year":"2021","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2023.101163_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246035","article-title":"Obinutuzumab, high-dose methylprednisolone (HDMP), and Lenalidomide for the treatment of patients with Richter\u2019s syndrome","volume":"14","author":"Heyman","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0405","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.98","article-title":"Ibrutinib has some activity in Richter\u2019s syndrome","volume":"5","author":"Giri","year":"2015","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.blre.2023.101163_bb0410","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","article-title":"A phase two study of high dose blinatumomab in Richter\u2019s syndrome","volume":"36","author":"Thompson","year":"2022","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0415","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12885-019-5717-y","volume":"19","author":"Appleby","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.blre.2023.101163_bb0420","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.blre.2023.101163_bb0425","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia."},{"issue":"364","key":"10.1016\/j.blre.2023.101163_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.blre.2023.101163_bb0435","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0440","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fernandez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.blre.2023.101163_bb0445","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.blre.2023.101163_bb0450","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2023.101163_bb0455","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"28","key":"10.1016\/j.blre.2023.101163_bb0460","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101163_bb0465","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1038\/ncomms14756","article-title":"Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.blre.2023.101163_bb0470","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1182\/bloodadvances.2021004528","article-title":"Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab","volume":"5","author":"Bruscaggin","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.blre.2023.101163_bb0475","doi-asserted-by":"crossref","first-page":"17936","DOI":"10.18632\/oncotarget.15316","article-title":"Using high-sensitivity sequencing for the detection of mutations in BTK and PLCgamma2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors","volume":"8","author":"Albitar","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2023.101163_bb0480","article-title":"Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones","volume":"18","author":"Trummer","year":"2022","journal-title":"Leuk Res Rep"},{"issue":"19","key":"10.1016\/j.blre.2023.101163_bb0485","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1158\/1078-0432.CCR-22-0433","article-title":"Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib and venetoclax","volume":"28","author":"Furstenau","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2023.101163_bb0490","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2704","article-title":"The development of liquid biopsy for research and clinical practice in lymphomas: report of the 15-ICML workshop on ctDNA","volume":"38","author":"Rossi","year":"2020","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101163_bb0495","first-page":"785","article-title":"Hodgkin\u2019s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group","volume":"34","author":"Tadmor","year":"2014","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.blre.2023.101163_bb0500","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13016","article-title":"Hodgkin\u2019s variant of Richter\u2019s transformation during ibrutinib therapy in a series of CLL patients; the polish adult Leukemia group report (PALG)","volume":"100","author":"Jamroziak","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2023.101163_bb0505","first-page":"12","article-title":"Case report: sequential development of three mature lymphoid neoplasms in a single patient: clonal relationship and molecular insights","author":"Salvetti","year":"2022","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.blre.2023.101163_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164674","article-title":"Hodgkin lymphoma and hairy cell Leukemia arising from chronic lymphocytic Leukemia: case reports and literature review","volume":"11","author":"D\u2019Addona","year":"2022","journal-title":"J Clin Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:29:41Z","timestamp":1759436981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":102,"alternative-id":["S0268960X23001339"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101163","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Richter's transformation: Transforming the clinical landscape","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101163"}}